Contact info@epaad.org for more information
  • Home
  • APOE U19
    • What is APOE?
    • Research Program
    • Publications
  • Data
    • Gene Expresssion Database
    • Lipid Abundance Database
    • Bulk RNA-seq Database
    • Metabolomics Database
    • APOE U19 Publications Database
    • Human CSF Immune Activation Markers
    • Other
    • Brain Lysate Data
      • Soluble Fraction: TBS
      • Detergent Soluble Fraction: TBS-X
      • Insoluble Fraction: Neutralized FA
  • Resources
    • Antibodies
    • Animal Models
    • IPSC Models
  • Protocols
    • iPSC Protocols
    • Published Methods
  • About us
  • Home
  • APOE U19
    • What is APOE?
    • Research Program
    • Publications
  • Data
    • Gene Expresssion Database
    • Lipid Abundance Database
    • Bulk RNA-seq Database
    • Metabolomics Database
    • APOE U19 Publications Database
    • Human CSF Immune Activation Markers
    • Other
    • Brain Lysate Data
      • Soluble Fraction: TBS
      • Detergent Soluble Fraction: TBS-X
      • Insoluble Fraction: Neutralized FA
  • Resources
    • Antibodies
    • Animal Models
    • IPSC Models
  • Protocols
    • iPSC Protocols
    • Published Methods
  • About us

ApoE and TDP-43

Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43. Wennberg, A. M., Tosakulwong, N., Lesnick, T. G., Murray, M. E., Whitwell, J. L., Liesinger, A. M., Petrucelli, L., Boeve, B. F., Parisi, J. E., Knopman, D. S., Petersen, R. C., Dickson, D. W., & Josephs, K. A. (2018).  JAMA neurology, 75(11), 13471354.

Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study. Yang, H. S., Yu, L., White, C. C., Chibnik, L. B., Chhatwal, J. P., Sperling, R. A., Bennett, D. A., Schneider, J. A., & De Jager, P. L. (2018).  The Lancet. Neurology, 17(9), 773781.

Fitting TDP-43 into the APOE ε4 and neurodegeneration story. Josephs K. A. (2018).  The Lancet. Neurology, 17(9), 735737.

This repository is under review for potential modification in compliance with Administration directives.

Dismiss

info@epaad.org

Copyright © 2026 EPAAD